| Overcoming Depression with 5-HT2A Receptor Ligands A Zięba, P Stępnicki, D Matosiuk, AA Kaczor International Journal of Molecular Sciences 23 (1), 10, 2021 | 29 | 2021 |
| What are the challenges with multi-targeted drug design for complex diseases? A Zięba, P Stępnicki, D Matosiuk, AA Kaczor Expert Opinion on Drug Discovery 17 (7), 673-683, 2022 | 17 | 2022 |
| The role of genetics in the development and pharmacotherapy of depression and its impact on drug discovery A Zięba, D Matosiuk, AA Kaczor International journal of molecular sciences 24 (3), 2946, 2023 | 16 | 2023 |
| Current approaches and tools used in drug development against parkinson’s disease O Koszła, P Stępnicki, A Zięba, A Grudzińska, D Matosiuk, AA Kaczor Biomolecules 11 (6), 897, 2021 | 14 | 2021 |
| Docking-based 3D-QSAR studies for 1, 3, 4-oxadiazol-2-one derivatives as FAAH inhibitors A Zięba, T Laitinen, JZ Patel, A Poso, AA Kaczor International journal of molecular sciences 22 (11), 6108, 2021 | 10 | 2021 |
| The Universal 3D QSAR Model for Dopamine D2 Receptor Antagonists A Zięba, J Żuk, D Bartuzi, D Matosiuk, A Poso, AA Kaczor International Journal of Molecular Sciences 20 (18), 4555, 2019 | 7 | 2019 |
| Multitarget derivatives of D2AAK1 as potential antipsychotics: the effect of substitution in the indole moiety M Kondej, TM Wróbel, KM Targowska‐Duda, A Leandro Martínez, ... ChemMedChem 17 (15), e202200238, 2022 | 6 | 2022 |
| Caspases in Alzheimer’s disease: mechanism of activation, role, and potential treatment P Wójcik, MK Jastrzębski, A Zięba, D Matosiuk, AA Kaczor Molecular Neurobiology, 1-20, 2023 | 3 | 2023 |
| Discovery of novel arylpiperazine-based DA/5-HT modulators as potential antipsychotic agents–Design, synthesis, structural studies and pharmacological profiling P Stępnicki, KM Targowska-Duda, AL Martínez, A Zięba, ... European Journal of Medicinal Chemistry 252, 115285, 2023 | 3 | 2023 |
| Novel multi-target ligands of dopamine and serotonin receptors for the treatment of schizophrenia based on indazole and piperazine scaffolds–synthesis, biological activity, and … P Stępnicki, O Wronikowska-Denysiuk, A Zięba, KM Targowska-Duda, ... Journal of Enzyme Inhibition and Medicinal Chemistry 38 (1), 2209828, 2023 | 2 | 2023 |
| Current Approaches and Tools Used in Drug Development against Parkinson’s Disease. Biomolecules 2021, 11, 897 O Koszła, P Stępnicki, A Zięba, A Grudzińska, D Matosiuk, AA Kaczor s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2021 | 1 | 2021 |
| Sampling and Scoring in Protein–Protein Docking A Zięba, D Matosiuk Protein-Protein Docking: Methods and Protocols, 15-26, 2024 | | 2024 |
| Discovery and in vitro Evaluation of Novel Serotonin 5‐HT2A Receptor Ligands Identified Through Virtual Screening A Zięba, D Bartuzi, P Stępnicki, D Matosiuk, TM Wróbel, T Laitinen, ... ChemMedChem, e202400080, 2024 | | 2024 |
| The application of WaterMap-guided structure-based virtual screening in novel drug discovery AA Kaczor, A Zięba, D Matosiuk Expert Opinion on Drug Discovery 19 (1), 73-83, 2024 | | 2024 |
| Development and Characterization of Novel Selective, Non-Basic Dopamine D2 Receptor Antagonists for the Treatment of Schizophrenia P Stępnicki, S Wośko, A Bartyzel, A Zięba, D Bartuzi, K Szałaj, TM Wróbel, ... Molecules 28 (10), 4211, 2023 | | 2023 |
| Application of the 3D-QSAR methods for the development of novel, more potent D2 receptor antagonists. A Zieba, D Matosiuk, A Kaczor MDPI, 2021 | | 2021 |
| PREPARATY HORMONALNE W DOPINGU WYDOLNOŚCIOWYM A Zięba, E Bury, E Kędzierska, J Orzelska-Górka, E Gibuła-Bruzda Nauki Przyrodnicze i Medyczne: Żywienie, sport oraz zdrowie, 98, 0 | | |
